Dataset Information

2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.

ABSTRACT: The 2nd Annual Antibodies for Cancer Therapy symposium, organized again by Cambridge Healthtech Institute as part of the Protein Engineering Summit, was held in Boston, USA from April 30th to May 1st, 2012. Since the approval of the first cancer antibody therapeutic, rituximab, fifteen years ago, eleven have been approved for cancer therapy, although one, gemtuzumab ozogamicin, was withdrawn from the market. The first day of the symposium started with a historical review of early work for lymphomas and leukemias and the evolution from murine to human antibodies. The symposium discussed the current status and future perspectives of therapeutic antibodies in the biology of immunoglobulin, emerging research on biosimilars and biobetters, and engineering bispecific antibodies and antibody-drug conjugates. The tumor penetration session was focused on the understanding of antibody therapy using ex vivo tumor spheroids and the development of novel agents targeting epithelial junctions in solid tumors. The second day of the symposium discussed the development of new generation recombinant immunotoxins with low immunogenicity, construction of chimeric antigen receptors, and the proof-of-concept of 'photoimmunotherapy'. The preclinical and clinical session presented antibodies targeting Notch signaling and chemokine receptors. Finally, the symposium discussed emerging technologies and platforms for therapeutic antibody discovery.

SUBMITTER: Ho M

PROVIDER: S-EPMC3499296 | biostudies-literature | 2012 Sep-Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.

Ho Mitchell M Royston Ivor I Beck Alain A

mAbs 20120806 5

The 2nd Annual Antibodies for Cancer Therapy symposium, organized again by Cambridge Healthtech Institute as part of the Protein Engineering Summit, was held in Boston, USA from April 30th to May 1st, 2012. Since the approval of the first cancer antibody therapeutic, rituximab, fifteen years ago, eleven have been approved for cancer therapy, although one, gemtuzumab ozogamicin, was withdrawn from the market. The first day of the symposium started with a historical review of early work for lympho ...[more]

PMID: 22864478

Similar Datasets

Project description:Table of contentsI1 Proceedings of the Fifteenth Annual UT- KBRIN Bioinformatics Summit 2016Eric C. Rouchka, Julia H. Chariker, Benjamin J. Harrison, Juw Won ParkP1 CC-PROMISE: Projection onto the Most Interesting Statistical Evidence (PROMISE) with Canonical Correlation to integrate gene expression and methylation data with multiple pharmacologic and clinical endpointsXueyuan Cao, Stanley Pounds, Susana Raimondi, James Downing, Raul Ribeiro, Jeffery Rubnitz, Jatinder LambaP2 Integration of microRNA-mRNA interaction networks with gene expression data to increase experimental powerBernie J Daigle, Jr.P3 Designing and writing software for in silico subtractive hybridization of large eukaryotic genomesDeborah Burgess, Stephanie Gehrlich, John C CarmenP4 Tracking the molecular evolution of Pax geneNicholas Johnson; Chandrakanth EmaniP5 Identifying genetic differences in thermally dimorphic and state specific fungi using in silico genomic comparisonStephanie Gehrlich, Deborah Burgess, John C CarmenP6 Identification of conserved genomic regions and variation therein amongst Cetartiodactyla species using next generation sequencingKalpani De Silva, Michael P Heaton, Theodore S KalbfleischP7 Mining physiological data to identify patients with similar medical events and phenotypesTeeradache Viangteeravat, Rahul Mudunuri, Oluwaseun Ajayi, Fatih Şen, Eunice Y HuangP8 Smart brief for home health monitoringMohammad Mohebbi, Luaire Florian, Douglas J Jackson, John F NaberP9 Side-effect term matching for computational adverse drug reaction predictionsAKM Sabbir, Sally R EllingsonP10 Enrichment vs robustness: A comparison of transcriptomic data clustering metricsYuping Lu, Charles A Phillips, Michael A LangstonP11 Deep neural networks for transcriptome-based cancer classificationRahul K Sevakula, Raghuveer Thirukovalluru, Nishchal K. Verma, Yan CuiP12 Motif discovery using K-means clusteringMohammed Sayed, Juw Won ParkP13 Large scale discovery of active enhancers from nascent RNA sequencingJing Wang, Qi Liu, Yu ShyrP14 Computationally characterizing genomic pipelines and benchmarking results using GATK best practices on the high performance computing cluster at the University of KentuckyXiaofei Zhang, Sally R EllingsonP15 Development of approaches enabling the identification of abnormal gene expression from RNA-Seq in personalized oncologyNaresh Prodduturi, Gavin R Oliver, Diane Grill, Jie Na, Jeanette Eckel-Passow, Eric W KleeP16 Processing RNA-Seq data of plants infected with coffee ringspot virusMichael M Goodin, Mark Farman, Harrison Inocencio, Chanyong Jang, Jerzy W Jaromczyk, Neil Moore, Kelly SovacoolP17 Comparative transcriptomics of three Acinetobacter baumanii clinical isolates with different antibiotic resistance patternsLeon Dent, Mike Izban, Sammed Mandape, Shruti Sakhare, Siddharth Pratap, Dana MarshallP18 Metagenomic assessment of possible microbial contamination in the equine reference genome assemblyM Scotty DePriest, James N MacLeod, Theodore S KalbfleischP19 Molecular evolution of cancer driver genesChandrakanth Emani, Hanady Adam, Ethan Blandford, Joel Campbell, Joshua Castlen, Brittany Dixon, Ginger Gilbert, Aaron Hall, Philip Kreisle, Jessica Lasher, Bethany Oakes, Allison Speer, Maximilian ValentineP20 Biorepository Laboratory Information Management SystemNaga Satya V Rao Nagisetty, Rony Jose, Teeradache Viangteeravat, Robert Rooney, David Hains

Project description:The CHARGE consortium is an investigator-initiated collaboration to facilitate meta-analyses of genome-wide association studies (GWAS) and genomic analyses based on next generation sequencing (NGS), among multiple large and well-phenotyped population-based cohort studies around the world (http://www.chargeconsortium.com). Within the neuro-CHARGE working group, we are presenting an update of ongoing genomic studies on MRI-markers of cerebrovascular disease. Large population-based studies have shown that the burden of cerebrovascular disease extends far beyond that of clinical stroke. MRI-markers of cerebral small vessel disease, such as white matter hyperintensities (WMH), small subcortical brain infarcts, microbleeds, or dilated perivascular spaces, are particularly frequent in older community persons. These markers portend an increased risk of stroke, dementia, and premature death, and were shown to have a high heritability, especially WMH burden. Interestingly recent work has revealed genetic risk variants between WMH burden and stroke. To account for the major role of high blood pressure in the occurrence of WMH, we are performing a GWAS of WMH burden stratified on hypertension status, as well as a joint meta-analysis to account for gene-environment interaction with hypertension. Moreover, based on prior epidemiologic and histologic data suggesting that the pathogenesis of WMH may differ according to their location, we are running separate GWAS for periventricular and deep WMH burden. A GWAS of cerebral microbleeds is being finalized. We are also exploring the role of vascular risk factors in the occurrence of dementia by examining the relation of genetic risk scores for these factors with MRI-markers of brain aging and cerebrovascular disease. Finally, several NGS projects are being conducted to identify rare variants associated with WMH burden and lacunar brain infarcts. Additional projects are also currently being designed, including GWAS of novel MRI phenotypes, such as composite measures of cerebral small vessel disease, as well as lifetime, and epigenomic approaches.

Dataset Information

2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.

Publications

2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure